School of Public Health
Estimating the cost of illness for typhoid fever in Nepal: A sub-study of the Typhoid Vaccine Acceleration Consortium (TyVAC)
Typhoid fever represents a substantial epidemiologic and economic burden in Nepal, and while understanding of the disease burden is growing, data quantifying the economic burden is limited. The Typhoid Vaccine Acceleration Consortium Cost of Illness study (TyVAC-COI), led by Johns Hopkins Bloomberg School of Public Health International Vaccine Access Center as part of the broader TyVAC study led by University of Maryland and Oxford University, aims to generate new evidence on the economic burden of enteric fever (i.e., typhoid and paratyphoid fever) in Nepal. The study will estimate the cost of illness from the health care system and household perspectives and estimate the catastrophic impact on households through primary data collection. We are collecting data on health facility expenditures and utilization of health services for treating enteric fever from facility administrators, medical and non-medical staff, and laboratory technicians. We are also collecting out-of-pocket expenditures, productivity loss, and household impact data from patients with blood culture-confirmed typhoid and paratyphoid presenting to a participating study health facility using a facility-based cohort study design. This study is being conducted at two hospitals in Kathmandu (Patan Hospital and Kanti Children's Hospital), three public ward clinics, and one private clinic. Results from this study will be used to inform policy decisions on typhoid control interventions, including introducing the new Typbar typhoid conjugate vaccine.
This project is being conducted alongside a vaccine effectiveness trial, led by Oxford University.
PI Mentor: Cristina Garcia